Outline of JUA clinical guidelines for benign prostatic hyperplasia


  • This abstract is reproduced from the original version of JUA Clinical Guidelines for Benign Prostatic Hyperplasia: doi: 10.1111/j.1442-2042.2011.02861.x.

  • The complete English version is available at http://onlinelibrary.wiley.com/doi/10.1111/iju.2011.18.issue-11/issuetoc

  • This is a translated summary of a full guideline first published as a book in Japanese by The Japanese Urological Association, Clinical guidelines for benign prostatic hyperplasia, 2011. RichHill Medical, Tokyo.

Yukio Homma M.D., Department of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Email: homma-uro@umin.ac.jp


The Japanese Urological Association has developed Clinical Guidelines for Benign Prostatic Hyperplasia (BPH) for men with suspected BPH, which have been abridged and translated into English. This article is a shortened version of the English translation. The Guidelines were formulated on the basis of evidence retrieved from the PubMed database between 1995 and 2009, as well as other relevant sources. The target patients of these Guidelines are men with suspected BPH, and the target users are urologists. A mandatory assessment should include a medical history, a physical examination, the completion of symptom and quality of life questionnaires, urinalysis, prostate ultrasonography, measurement of serum prostate specific antigen and postvoid residual urine, and an uroflowmetry. Optional tests include a bladder diary, the measurement of serum creatinine, and upper urinary tract ultrasonography. Care should be taken to not overlook coexisting diseases such as an infection or malignancy that may obscure the diagnosis. Treatment should consist of conservative therapy or the use of medications such as α1-adrenoceptor antagonists, or both. The use of 5α-reductase inhibitors or anticholinergic agents should be considered in patients with an enlarged prostate (>30 mL) or overactive bladder symptoms (overactive bladder symptom score ≥6), respectively. Surgical intervention is indicated when non-surgical treatments fail to provide sufficient symptomatic relief and bladder outlet obstruction is highly suspected.